DelveInsight reports that over 10 key companies are actively developing more than 10 therapeutic candidates for Lennox-Gastaut Syndrome (LGS).
Lennox Gastaut Syndrome Overview:
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that usually develops in infancy or early childhood. Children with LGS often experience cognitive impairments, developmental delays, and behavioral difficulties. Symptoms typically emerge between ages 3 and 5, with multiple seizure types occurring frequently throughout the day. Diagnosis involves a thorough clinical evaluation, including patient history, physical and neurological examinations, and may utilize advanced imaging techniques such as electroencephalography (EEG) and magnetic resonance imaging (MRI).
Treatment for LGS primarily includes anti-epileptic drugs (AEDs), dietary therapy (most commonly the ketogenic diet), and surgical or device-based interventions such as vagus nerve stimulation (VNS) or corpus callosotomy. In select cases, resective surgery may also be considered.
Request for a detailed insights report on Lennox Gastaut Syndrome pipeline insights
"Lennox Gastaut Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lennox Gastaut Syndrome Therapeutics Market.
Key Takeaways from the Lennox Gastaut Syndrome Pipeline Report
-
DelveInsight’s Lennox-Gastaut Syndrome (LGS) pipeline report highlights a dynamic landscape with over 10 companies developing more than 10 therapeutic candidates.
-
Key players such as Takeda, Marinus Pharmaceuticals, SK biopharmaceuticals, CuroNZ, TAHO Pharmaceuticals, Axium Pharmaceuticals, and others are advancing new drugs to enhance treatment options for LGS.
-
Promising pipeline candidates in various stages of development include Soticlestat and others.
-
In March 2023, Marinus Pharmaceuticals received FDA Orphan Drug Designation for ganaxolone, a neuroactive steroid and GABA_A receptor modulator with anti-seizure properties, for the treatment of LGS. Marinus plans to launch a multiple ascending dose study of a second-generation ganaxolone formulation and finalize its clinical program design for LGS later in 2023.
Lennox Gastaut Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Lennox Gastaut Syndrome Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lennox Gastaut Syndrome treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lennox Gastaut Syndrome market.
Download our free sample page report on Lennox Gastaut Syndrome pipeline insights
Lennox Gastaut Syndrome Emerging Drugs
-
Soticlestat: Takeda
Lennox Gastaut Syndrome Companies
Over ten leading companies are actively pursuing therapies for Lennox-Gastaut Syndrome (LGS), with Takeda advancing the most advanced candidates, currently in Phase III clinical trials.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Lennox Gastaut Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Lennox Gastaut Syndrome Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Lennox Gastaut Syndrome Therapies and Key Companies: Lennox Gastaut Syndrome Clinical Trials and advancements
Lennox Gastaut Syndrome Pipeline Therapeutic Assessment
• Lennox Gastaut Syndrome Assessment by Product Type
• Lennox Gastaut Syndrome By Stage
• Lennox Gastaut Syndrome Assessment by Route of Administration
• Lennox Gastaut Syndrome Assessment by Molecule Type
Download Lennox Gastaut Syndrome Sample report to know in detail about the Lennox Gastaut Syndrome treatment market @ Lennox Gastaut Syndrome Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Lennox Gastaut Syndrome Current Treatment Patterns
4. Lennox Gastaut Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Lennox Gastaut Syndrome Late-Stage Products (Phase-III)
7. Lennox Gastaut Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lennox Gastaut Syndrome Discontinued Products
13. Lennox Gastaut Syndrome Product Profiles
14. Lennox Gastaut Syndrome Key Companies
15. Lennox Gastaut Syndrome Key Products
16. Dormant and Discontinued Products
17. Lennox Gastaut Syndrome Unmet Needs
18. Lennox Gastaut Syndrome Future Perspectives
19. Lennox Gastaut Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Lennox Gastaut Syndrome Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
